These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 24941480)

  • 1. [The value of the utility of estimating QALYs: an open question].
    Mennini FS
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24941480
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems and solutions in calculating quality-adjusted life years (QALYs).
    Prieto L; Sacristán JA
    Health Qual Life Outcomes; 2003 Dec; 1():80. PubMed ID: 14687421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [QALYS or not QALYS: that is the question?].
    Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
    Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of utility: assumptions underlying preferences and quality adjusted life years.
    Guillemin F
    J Rheumatol; 1999 Sep; 26(9):1861-3. PubMed ID: 10493660
    [No Abstract]   [Full Text] [Related]  

  • 6. Italian population-based values of EQ-5D health states.
    Scalone L; Cortesi PA; Ciampichini R; Belisari A; D'Angiolella LS; Cesana G; Mantovani LG
    Value Health; 2013; 16(5):814-22. PubMed ID: 23947975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not all "quality-adjusted life years" are equal.
    Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
    J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new and more robust test of QALYs.
    Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
    J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life after stroke: review of the literature and implications for future research.
    Tseng MC; Lin HJ
    Acta Neurol Taiwan; 2007 Mar; 16(1):7-12. PubMed ID: 17486727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of health-related quality-of-life instrument and quality-adjusted life year calculation method on the number of life years gained in the critical care setting.
    Vainiola T; Roine RP; Pettilä V; Kantola T; Räsänen P; Sintonen H
    Value Health; 2011 Dec; 14(8):1130-4. PubMed ID: 22152183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility value and retinal detachment surgery.
    Zou H; Zhang X; Xu X; Liu H; Bai L; Xu X
    Ophthalmology; 2011 Mar; 118(3):601-601.e2. PubMed ID: 21376245
    [No Abstract]   [Full Text] [Related]  

  • 14. Incorporating feelings related to the uncertainty about future health in utility measurement.
    Gandjour A
    Health Econ; 2008 Oct; 17(10):1207-13. PubMed ID: 18074407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capabilities as menus: a non-welfarist basis for QALY evaluation.
    Bleichrodt H; Quiggin J
    J Health Econ; 2013 Jan; 32(1):128-37. PubMed ID: 23202258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods and issues associated with the use of quality-adjusted life-years.
    Revicki DA; Lenderking WR
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):105-14. PubMed ID: 22280200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk attitudes to treatment among patients with severe intermittent claudication.
    Letterstål A; Forsberg C; Olofsson P; Wahlberg E
    J Vasc Surg; 2008 May; 47(5):988-94. PubMed ID: 18455642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II.
    Noyes K; Corona E; Zwanziger J; Hall WJ; Zhao H; Wang H; Moss AJ; Dick AW;
    Med Care; 2007 May; 45(5):377-85. PubMed ID: 17446823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [How are quality-adjusted life years defined in German studies?].
    Schwappach DL; Boluarte TA
    Dtsch Med Wochenschr; 2006 Sep; 131(37):2004-9. PubMed ID: 16960766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in quality-adjusted life-years lost contributed by smoking and obesity.
    Jia H; Lubetkin EI
    Am J Prev Med; 2010 Feb; 38(2):138-44. PubMed ID: 20117569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.